Furui Co.,Ltd(SZ:300049)2022-12-06 07:31Group 1: Company Overview and Investment Activities - Inner Mongolia Furu Medical Technology Co., Ltd. is focused on long-term development, with major shareholders expressing confidence despite a low shareholding ratio [2] - The company has terminated its non-public stock issuance project but continues to advance its fundraising projects, now with closer cooperation with hospitals [2] - The company is involved in internet medical services and chronic disease management, aiming to provide more patient services [2] Group 2: Medical Services and Internet Platform - The company is still investing in liver disease management services, which are expected to contribute long-term and flexible benefits [3] - The "Love Liver for Life" internet platform is crucial for accumulating medical resources and is seen as a significant part of the medical service model [3] - The company has increased its investment in the internet medical platform since the second half of last year, with expectations for stable operations depending on healthcare policy reforms [3] Group 3: Financial Performance and Market Strategy - In 2016, the overseas medical project served over 1,000 patients, generating approximately 30 million yuan in revenue [3] - The company aims to provide comprehensive solutions for liver disease patients rather than focusing solely on drug development [4] - The company reported significant growth in sales in the U.S. market, with some growth also in China and Europe [4] Group 4: Research and Development - The company is primarily investing in the development of the FibroScan series and the construction of the internet medical platform [4] - Echosens, a major subsidiary, has seen substantial revenue growth but maintained stable profits due to increased expenses [4] - The company plans to continue using natural cordyceps as a raw material despite the lower cost of artificial alternatives [4] Group 5: Future Outlook and Strategic Partnerships - Echosens is focused on providing comprehensive solutions for liver disease diagnosis, with ongoing projects in collaboration with GE Healthcare [5] - The IPO expenses for Echosens in 2016 were over 3 million euros, with other costs impacting current profits [5] - The major shareholder is considering increasing control over the company when opportunities arise [5]